Target intelligence / Profile preview

Sideroflexin-5 (SFXN5)

Target
SFXN5
Molecular classification
Transporter, Mitochondrial transmembrane protein, Solute carrier family protein (SLC56 family)
01

Overview

Sideroflexin-5 is a member of the Sideroflexin (SFXN) family, which consists of highly conserved multi-spanning transmembrane proteins mainly located in the mitochondrial inner membrane. SFXN5 is primarily characterized as a mitochondrial amino-acid transporter and mediator of citrate transmembrane transport. It does not function as a serine transporter, unlike some other family members (e.g., SFXN1). In brown adipose tissue, SFXN5 may regulate thermogenesis by supporting mitochondrial glycerol-3-phosphate utilization. Current research links the SFXN family to essential metabolic processes such as iron uptake, redox balance, and amino acid metabolism, but SFXN5 remains the least well-studied member. Disease associations include mitochondrial deficiency syndromes and possible roles in neurodegenerative and cancer processes, based on emerging expression data and known implications from other family members. There are currently no approved drugs targeting SFXN5 directly, nor is it an established biomarker or well-defined safety target.

Other names
SFXN5Sideroflexin-5BBG-TCCSLC56A5ENSG00000144040
02

Mechanism of action

Not established for drugs; therapies that could influence iron or mitochondrial metabolism may be speculative

03

Biological functions

Citrate transportMitochondrial amino acid transportRegulation of mitochondrial thermogenesis (in brown adipose tissue)Maintenance of mitochondrial metabolism and potentially iron homeostasis (by homology to other sideroflexins)
04

Disease associations

Cancer (dysregulation in other Sideroflexins has cancer relevance; SFXN5 is implicated by expression)Mitochondrial disorders (e.g., Combined oxidative phosphorylation deficiency 18)Neurodegenerative disease (e.g., Parkinson disease, late-onset)
05

Safety considerations

Unknown; insufficient data for specific safety concerns, but mitochondrial transport proteins as drug targets may need careful assessment regarding metabolic side effects
06

Interacting drugs

None directly known; no drugs as of current data are reported to target Sideroflexin-5 specifically
07

Biomarkers

Not established; SFXN5 is not currently recognized as a clinical biomarker

Beyond the preview

Go deeper on Sideroflexin-5 (SFXN5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sideroflexin-5 (SFXN5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call